terations of specifi c granules, eosinophils are able to change their morphology in response to different agonists. Figure 2 shows shape changes in eosinophils stimulated by eotaxin, a potent eosinophil activator.
Eosinophils are leukocytes which, when stimulated with cytokines or chemokines, become activated and release mediators stored in their dominant population of cytoplasmic granules (termed specifi c or secondary granules) [1] . The morphology of activated eosinophils is quite distinct. In a range of infl ammatory and allergic disorders or upon physiological stimulation, activated eosinophils are generally seen as cells full of granules, but these structures are undergoing progressive losses of their contents with retention of granule outer membranes, a process known as 'piecemeal degranulation' [2, 3] ( fi g. 1 a). As a result, a mixed population of intact ( fi g. 1 a, asterisks) and enlarged, emptying ( fi g. 1 a, arrows) granules is always visualized in cell sections [3] . Also, a decrease of specifi c granule numbers can occur [3] . A rare view of an activated eosinophil is shown in fi gure 1 b taken from a hypereosinophilic subject. While a single specifi c granule (Gr) is seen in the cytoplasm in conjunction with an osmiophilic lipid body (LB), the cell surface shows elaborate projections indicative of activation. Vesiculotubular structures ( fi g. 1 b, arrowheads), termed 'eosinophil sombrero vesicles' (EoSV) and recently associated with the eosinophil secretory pathway [4, 5] reside in the cytoplasm. This vesicle population is unique to eosinophils and allows the prompt identifi cation of these cells by electron microscopy when specifi c granules are not present [3] .
Shape changes are another hallmark of activated human eosinophils. In parallel with the morphological al- The cell shows a broadened cytoplasmic area fi lled with granules and displaying broad surface processes. c Granule-free uropod is present. n = Nucleus. a -c ! 18,000. Eosinophils were isolated from the peripheral blood of healthy (fi g. 1a, 2a, c) or hypereosinophilic (fi g. 1b) donors by negative selection, stimulated (fi g. 1a, 2a, c ) or not (fi g. 1b) with recombinant human eotaxin and prepared for transmission electron microscopy using standard methods.
